Bipolar Disorder
📧 Sign up to get email alerts when something new happens for Bipolar Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2018-12-20FDA Approved: LITHIUM CARBONATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Lithium Carbonate from Hikma Pharmaceuticals USA Inc., a generic drug product.
-
CLINICAL_TRIALS trial_result · 2018-12-14Clinical Trial Update: Acamprosate vs. Placebo in Bipolar Alcoholics [Phase 4]
Phase 4 trial comparing acamprosate to placebo in individuals with alcohol dependence and bipolar disorder; study completed with results pos…
-
CLINICAL_TRIALS trial_result · 2018-12-12Clinical Trial Update: Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder [Phase 3]
A Phase 3 trial comparing valproate to risperidone in young children with bipolar disorder has completed.
-
CLINICAL_TRIALS trial_result · 2018-12-12Clinical Trial Update: Improving Mental Health Outcomes: Building an Adaptive Implementation Strategy [NA]
Clinical trial on improving mental health outcomes through an adaptive implementation strategy has terminated; results posted in 2018.
-
FDA approval · 2018-12-07FDA Approved: LITHIUM CARBONATE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA granted a supplemental approval for Lithium Carbonate from Rising Pharma Holdings, Inc. under ANDA205663.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-12-07FDA Approved: LITHIUM CARBONATE ER — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental application for an extended-release version of lithium carbonate (Lithium Carbonate ER) from Glenmark Pharmaceut…
-
FDA approval · 2018-11-30FDA Approved: LAMOTRIGINE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's original application for a generic lamotrigine product.
-
FDA approval · 2018-11-28FDA Approved: VRAYLAR — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for VRYALR (cariprazine) by Allergan, Inc., granting changes to the drug’s labeling.
-
FDA approval · 2018-11-19FDA Approved: OLANZAPINE — Original Application (HEC Pharm USA Inc.)
The FDA approved the original ANDA application for olanzapine, granting generic status to HEC Pharm USA Inc. for this antipsychotic drug.
-
FDA approval · 2018-11-05FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for GEODON (ziprasidone) submitted by Viatris Specialty LLC.
-
FDA approval · 2018-11-05FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Geodon (ziprasidone) submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2018-11-05Clinical Trial Update: Get Moving and Get Well - Pilot Study [NA]
Pilot clinical trial update for a movement and wellness program in psychiatric conditions; study completed and results posted.
-
FDA approval · 2018-10-04FDA Approved: LITHIUM CARBONATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for lithium carbonate by Hikma Pharmaceuticals USA Inc. under NDA 017812.
-
FDA approval · 2018-10-04FDA Approved: LITHIUM CARBONATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Lithium Carbonate submitted by Hikma Pharmaceuticals USA Inc.
-
CLINICAL_TRIALS trial_result · 2018-10-02Clinical Trial Update: Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder [Phase 4]
Clinical trial update comparing clozapine with other atypical antipsychotics for bipolar disorder in Phase 4.
-
FDA approval · 2018-09-28FDA Approved: QUETIAPINE EXTENDED-RELEASE — Original Application (AlignScience Pharma Inc.)
FDA approved AlignScience Pharma Inc.'s generic extended-release quetiapine tablets (ANDA 209497). The approval enables a generic version of…
-
FDA approval · 2018-09-10FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved chlorpromazine hydrochloride under an original application from Amneal Pharmaceuticals; approved indications include schizophre…
-
CLINICAL_TRIALS trial_result · 2018-08-31Clinical Trial Update: Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features [Phase 4]
Phase 4 trial comparing olanzapine+lithium versus chlorpromazine+lithium for first manic episode with psychotic features in bipolar/schizoaf…
-
CLINICAL_TRIALS trial_result · 2018-08-24Clinical Trial Update: Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients [Phase 3]
Phase 3 trial assessing efficacy, safety, and tolerability of an intramuscular aripiprazole formulation (OPC-14597) as maintenance treatment…
-
CLINICAL_TRIALS trial_result · 2018-08-14Clinical Trial Update: Treatment of Bipolar Mania in Older Adults [Phase 4]
Phase 4 clinical trial update on treatments for bipolar mania in older adults; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2018-08-10Clinical Trial Update: Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression [Phase 2]
A Phase 2 trial evaluating vortioxetine as an add-on therapy shows improvement in symptoms for patients with bipolar depression.
-
CLINICAL_TRIALS trial_result · 2018-08-08Clinical Trial Update: Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder [Phase 3]
Phase 3 open-label study evaluating intramuscular aripiprazole (OPC-14597) for maintenance treatment in Bipolar I disorder has completed wit…
-
CLINICAL_TRIALS withdrawal · 2018-08-07Clinical Trial Update: Deep Brain Stimulation (DBS) for Treatment Resistant Bipolar Disorder [Phase 2, Phase 3]
A clinical trial investigating deep brain stimulation for treatment-resistant bipolar disorder was withdrawn after Phase 2/3 planning.
-
CLINICAL_TRIALS trial_result · 2018-08-01Clinical Trial Update: Inositol Hexaphosphate: A Novel Treatment Strategy for Bipolar Disorder? [Phase 1]
A Phase 1 clinical trial evaluating inositol hexaphosphate as a potential treatment for bipolar disorder has completed.
-
CLINICAL_TRIALS trial_result · 2018-07-31Clinical Trial Update: An Observational Modified Prescription-event Monitoring Study of Asenapine (Sycrest)
An observational prescription-event monitoring study of asenapine (Sycrest) for bipolar I disorder has completed.